Posted by Michael Wonder on 06 Jan 2023
Bicycle Therapeutics announces FDA fast track designation granted to BT8009 for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer
4 January 2023 - Bicycle Therapeutics today announced that the US FDA has granted fast track designation to Bicycle’s BT8009 monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer.
BT8009 is a potential first in class bicycle toxin conjugate targeting nectin-4, a protein that is highly expressed in urothelial cancer and other solid tumours.
